BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7487531)

  • 1. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST; Woodward WR; Nutt JG
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apomorphine in off state--clinical experience].
    Rudzińska M; Szczudlik A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations.
    Esteban Muñoz J; Martí MJ; Marín C; Tolosa E
    Clin Neuropharmacol; 1997 Jun; 20(3):245-52. PubMed ID: 9197948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
    Sharma JC; Macnamara L; Hasoon M; Vassallo M
    Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of apomorphine in movement disorders.
    Colosimo C; Merello M; Albanese A
    Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD; Chen JJ; Swope DM
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apomorphine in the treatment of Parkinson's disease.
    Hagell P; Odin P
    J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pragmatic use of apomorphine at the end of life.
    Dewhurst F; Lee M; Wood B
    Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
    Jenner P; Katzenschlager R
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid treatment of "wearing off" in Parkinson's disease.
    Swope DM
    Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.